Tecvayli 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/11010
Periodic Safety Update EU Single assessment - 
12/10/2023 
07/12/2023 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
/202302 
teclistamab 
II and PL 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/11010/202302. 
II/0006 
Update of sections 4.2, 5.1 and 5.2 of the SmPC in 
20/07/2023 
16/08/2023 
SmPC, Annex 
In patients who have a complete response or better for a 
order to update the posology recommendations to 
II and PL 
minimum of 6 months with teclistamab 1.5 mg/kg SC once 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
weekly, a reduced dosing frequency of 1.5 mg/kg SC every 
two weeks may be considered. 
For more information, please refer to the Summary of 
Product Characteristics. 
include the possibility of bi-weekly dosing, based on 
interim results from study 64007957MMY1001 
(MajesTEC-1); this is a phase 1/2, single-arm, open-
label, multicenter study of teclistamab administered 
as monotherapy to adult subjects with relapsed or 
refractory multiple myeloma. The Package Leaflet is 
updated accordingly. The RMP version 2.3 as also 
been submitted. In addition, the MAH took the 
opportunity to bring the PI in line with the latest QRD 
template version 10.3 and update the list of local 
representatives in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
R/0002 
Renewal of the marketing authorisation. 
25/05/2023 
24/07/2023 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Tecvayli, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
17/07/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0003 
Update of sections 4.2, 4.6 and 5.2 of the SmPC in 
22/06/2023 
16/08/2023 
SmPC and PL 
The dosing scheduling of teclistamab includes two step-up 
order to revise the dosing schedule, amend 
doses before the first full treatment or maintenance dose 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
recommendations on contraception and breast-
feeding and to update pharmacokinetic information, 
based on the latest data available; the Package 
Leaflet is updated accordingly. In addition, the MAH 
took the opportunity to introduce minor editorial 
changes to the PI and update the list of local 
representatives in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
can be given. A gap between two and seven days is 
required between the different steps in this schedule and a 
minimum of five days between weekly maintenance doses 
must be maintained. 
Women of child-bearing potential should use effective 
contraception and are advised not to breats-feed during 
treatment and for five months after the final dose of 
teclistamab. 
For more information, please refer to the Summary of 
Product Characteristics. 
IB/0004 
B.I.b.2.e - Change in test procedure for AS or 
19/05/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
19/01/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
